CEO Wenbin Jiang highlighted that "total revenue reached $52.3 million, representing a year-over-year increase of 2% compared to the same period in 2024." Jiang emphasized strong double-digit gains in ...
14h
bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume
SAN ANTONIO, November 05, 2025--bioAffinity Technologies announced the volume of CyPath® Lung tests processed in October ...
AI has the potential to transform life sciences commercialization, but only if we design it around people. Machines bring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback